



# Substrate Positioning by $Gln^{239}$ Stimulates Turnover in Factor Inhibiting HIF, an $\alpha$ KG-Dependent Hydroxylase

John A. Hangasky,<sup>†</sup> Geoffrey T. Ivison,<sup>†,‡</sup> and Michael J. Knapp<sup>\*,†</sup>

<sup>†</sup>Department of Chemistry, University of Massachusetts at Amherst, Amherst, Massachusetts 01003, United States

<sup>‡</sup>School of Natural Science, Hampshire College, Amherst, Massachusetts 01002, United States

**Supporting Information** 

**ABSTRACT:** Nonheme Fe(II)/ $\alpha$ KG-dependent oxygenases catalyze diverse reactions, typically inserting an O atom from O<sub>2</sub> into a C-H bond. Although the key to their catalytic cycle is the fact that binding and positioning of primary substrate precede O<sub>2</sub> activation, the means by which substrate binding stimulates turnover is not well understood. Factor Inhibiting HIF (FIH) is a Fe(II)/ $\alpha$ KG-dependent oxygenase that acts as a cellular oxygen sensor in humans by hydroxylating the target



residue Asn<sup>803</sup>, found in the C-terminal transactivation domain (CTAD) of hypoxia inducible factor-1. FIH-Gln<sup>239</sup> makes two hydrogen bonds with CTAD-Asn<sup>803</sup>, positioning this target residue over the Fe(II). We hypothesized the positioning of the side chain of CTAD-Asn<sup>803</sup> by FIH-Gln<sup>239</sup> was critical for stimulating O<sub>2</sub> activation and subsequent substrate hydroxylation. The steady-state characterization of five FIH-Gln<sup>239</sup> variants (Ala, Asn, Glu, His, and Leu) tested the role of hydrogen bonding potential and sterics near the target residue. Each variant exhibited a 20–1200-fold decrease in  $k_{cat}$  and  $k_{cat}/K_{M(CTAD)}$ , but no change in  $K_{M(CTAD)}$ , indicating that the step after CTAD binding was affected by point mutation. Uncoupled O<sub>2</sub> activation was prominent in these variants, as shown by large coupling ratios (C = [succinate]/[CTAD-OH] = 3-5) for each of the FIH-Gln<sup>239</sup>  $\rightarrow$  X variants. The coupling ratios decreased in D<sub>2</sub>O, indicating an isotope-sensitive inactivation for variants, not observed in the wild type. The data presented indicate that the proper positioning of CTAD-Asn<sup>803</sup> by FIH-Gln<sup>239</sup> is necessary to suppress uncoupled turnover and to support substrate hydroxylation, suggesting substrate positioning may be crucial for directing O<sub>2</sub> reactivity within the broader class of  $\alpha$ KG hydroxylases.

**N** onheme Fe(II)/ $\alpha$ KG-dependent oxygenases make up a large superfamily of enzymes catalyzing diverse reactions, including demethylations, hydroxylations, ring expansions, and epoxidations.<sup>1,2</sup> Many of these enzymes have important functions in human health because of their role in O<sub>2</sub> sensing,<sup>3,4</sup> DNA repair,<sup>5,6</sup> histone demethylation,<sup>7</sup> and RNA processing,<sup>8,9</sup> making this superfamily a growing class of therapeutic targets.<sup>10,11</sup> As the consensus chemical mechanism is an ordered sequential one, with O<sub>2</sub> reacting at the Fe prior to oxidation of the primary substrate (Scheme 1),<sup>12,13</sup> identifying features of the active site by which substrate binding stimulates O<sub>2</sub> reactivity is crucial to understanding the chemistry of this superfamily. An ideal enzyme for interrogating these connections is Factor Inhibiting HIF (FIH), because of the extensive contacts with the primary substrate.<sup>14</sup>

Human cells sense  $O_2$  through the hypoxia inducible factor (HIF) pathway, which is controlled by a small number of  $\alpha$ KG oxygenases, including FIH.<sup>15,16</sup> HIF is an  $\alpha\beta$  dimeric transcription factor that regulates numerous genes involved in tissue development, controlling processes such as glycolysis, erythropoiesis, and angiogenesis.<sup>1,17–19</sup> In the presence of  $O_2$ , FIH hydroxylates the  $\beta$ -carbon of HIF1 $\alpha$ -Asn<sup>803,20</sup> which is found in the C-terminal activation domain (CTAD) of HIF1 $\alpha$ . CTAD-Asn<sup>803</sup> hydroxylation blocks recruitment of the cAMP response element-binding protein (CREBP), preventing HIF-

dependent gene transcription.<sup>4,21</sup> The connection between CTAD-Asn<sup>803</sup> positioning and O<sub>2</sub> reactivity is critical to understanding how substrate stimulates O<sub>2</sub> activation in this enzyme superfamily, as well as illuminating FIH's role as an O<sub>2</sub> sensor.

The consensus chemical mechanism for FIH is based upon an array of kinetic and spectroscopic studies of FIH and other  $\alpha$ KG oxygenases. Kinetic studies of thymine hydroxylase, FIH, CAS, and TauD support the ordered, sequential binding of  $\alpha$ KG and primary substrate followed by O<sub>2</sub>.<sup>22-25</sup> Although  $\alpha$ KG, O<sub>2</sub>, and an oxidizable compound are all substrates for these enzymes, we will refer to the oxidizable substrate as the "primary substrate". Spectroscopic studies of CAS,<sup>26–28</sup> TfdA,<sup>29</sup> FIH,<sup>30</sup> and TauD<sup>31</sup> revealed that the Fe(II) released an aquo ligand after the primary substrate bound, creating a site for O<sub>2</sub> binding. Binding and activation of O2 lead to the oxidative decarboxylation of  $\alpha$ KG and the formation of a highly reactive ferryl intermediate (Scheme 1). Although the precise sequence of intermediates is not known, the ferryl intermediate has been observed in  $TauD^{32-34}$  and P4H,<sup>35</sup> demonstrating that H atom abstraction by the ferryl intermediate occurs,<sup>36</sup> with the next

Received: June 6, 2014 Revised: August 7, 2014 Published: August 13, 2014



step likely to be •OH rebound to hydroxylate the primary substrate.

The most intriguing feature of the consensus mechanism is that binding the primary substrate stimulates O2 reactivity.<sup>22,37,38</sup> Loss of an aquo ligand when the primary substrate is bound opens a coordination site for O2 binding, as observed upon binding of the primary substrate in several  $\alpha$ KGdependent oxygenases, including CytC3, TauD, CAS, and FIH.<sup>26,30,31</sup> Although aquo release is central to the widely accepted model for substrate-stimulated O2 activation,39 we note that simple ligand exchange is insufficient for O<sub>2</sub> activation in these enzymes. For example, substrate binding to FIH leads to only fractional release of the aquo ligand,<sup>30</sup> and mutagenesis suggests that hydrogen bond donors to the  $\alpha$ KG are necessary for full activity in this enzyme.<sup>40</sup> Computational studies<sup>41–44</sup> and mechanistic probes<sup>45–47</sup> further point to turnover being limited by steps after  $O_2$  binds to the Fe(II). These and related observations lead us to propose that substrate-stimulated O2 reactivity arises from bonding changes throughout the active site, ranging from aquo release at the iron cofactor to altered contacts in the second coordination sphere.

A focus of this research in our lab is to identify those active site features that change upon substrate binding to stimulate  $O_2$ activation in  $\alpha KG$  oxygenases. Although the precise sequence of intermediates formed during turnover is not known, we define O<sub>2</sub> activation as the steps between O<sub>2</sub> binding and oxidative decarboxylation (Scheme 1) by virtue of the irreversible chemistry; this step is depicted as the nucleophilic attack of the putative ferric superoxide on the  $\alpha$ -keto position of  $\alpha$ KG. On the basis of known crystal structures of FIH,<sup>14,48,49</sup> we have used point mutagenesis to identify several essential second-coordination sphere interactions in FIH, including those hydrogen bonding to Fe(II) ligands, as well as FIH-Gln<sup>239</sup>, an anchor residue that forms two hydrogen bonds with the target residue, CTAD-Asn<sup>803</sup> (Figure 1).<sup>14</sup> Intriguingly, disruption of this two-point hydrogen bond in the FIH-Gln<sup>239</sup>  $\rightarrow$  Asn point mutant led to a decrease in  $k_{\rm cat}$  of 250-fold, but a negligible change in  $K_{M(CTAD)}$ .<sup>40</sup> This was attributed to a combination of steric hindrance near the open coordination site on Fe(II) and incorrect CTAD positioning for the HAT step. Subsequently, it was shown that an irreversible step associated with O<sub>2</sub> activation was rate-limiting in wild-type FIH (WT-



**Figure 1.** CTAD-Asn<sup>803</sup> (CTAD, blue) positioned by FIH-Gln<sup>239</sup> (FIH, gray) over the active site. Hydrogen bonding distances are given in angstroms (Protein Data Bank entry 1H2L<sup>14</sup>).

FIH),<sup>25</sup> suggesting that the slower turnover for the Gln<sup>239</sup>  $\rightarrow$  Asn variant could arise from slower O<sub>2</sub> activation. This suggests the intriguing possibility that target residue position may stimulate O<sub>2</sub> activation and that the overall structure of the active site is crucial for O<sub>2</sub> activation.

This study tests the role of Gln<sup>239</sup> in substrate hydroxylation in  $\alpha$ KG oxygenases. As FIH hydroxylates a specific target residue within a large peptide (CTAD-Asn<sup>803</sup>), our focus was directed at this target residue pocket, formed by the side chains of FIH residues Tyr<sup>102</sup>, His<sup>199</sup>, Arg<sup>238</sup>, and Gln<sup>239</sup> (Figure 1). Five FIH-Gln<sup>239</sup>  $\rightarrow$  X variants were prepared (X = Ala, Asn, Glu, His, and Leu) to vary the bulk and hydrogen bonding potential within the target residue pocket. Although these variants exhibited significantly reduced steady-state rate constants that decreased monotonically with increasing residue bulk, CTAD binding affinity was unaffected by mutation. In contrast to the case in WT-FIH, O2 activation was appreciably uncoupled from CTAD hydroxylation in the variants; uncoupled  $O_2$  activation was partially suppressed in  $D_2O$ . These data establish that the proper orientation of CTAD-Asn<sup>803</sup> by FIH-Gln<sup>239</sup> is required for substrate hydroxylation, most likely because of the need for the proper target residue positioning during steps after  $O_2$  activation.

## EXPERIMENTAL PROCEDURES

**Materials.** All reagents were purchased from commercial vendors and were not further purified, with the exception of the 39-mer CTAD peptide. The 39-mer CTAD peptide corresponding to the C-terminal activation domain of human HIF1 $\alpha$ , (HIF1 $\alpha^{788-826}$ ) contained a Cys<sup>800</sup>  $\rightarrow$  Ala change (underlined) (DESGLPQLTSYD<u>A</u>EVNAPIQGSRNLLQGEE-LLRALDQVN). This was purchased as a desalted peptide from EZBiolab (Carmel, IN) with free N- and C-termini. The peptide was purified as previously described using reverse-phase high-performance liquid chromatography (RP-HPLC) to obtain >95% pure CTAD.<sup>25</sup> The 19-mer CTAD peptide corresponding to HIF1 $\alpha^{788-806}$  also contained a Cys<sup>800</sup>  $\rightarrow$  Ala change and was purchased at >95% purity from EZBiolab with free N- and C-termini. The CTAD-Asn<sup>803</sup>  $\rightarrow$  Gln peptide was the 19-mer sequence but contained the Asn<sup>803</sup>  $\rightarrow$  Gln change (DESGLPQLTSYDAEVQAPI).

**FIH Mutations.** The Stratagene QuikChange mutagenesis kit was used to introduce the mutations into the pET28a-FIH construct.<sup>50</sup> All mutations were sequenced (Genewiz) to confirm that the DNA sequence contained only the desired point mutation. Sequenced plasmids were transformed into BL21(DE3) cells for protein expression.

**Protein Expression and Purification.** WT-FIH and all variants were overexpressed in *Escherichia coli* with an N-terminal His<sub>6</sub> tag and purified as previously described.<sup>25</sup> Three additional residues (NH<sub>2</sub>-GlySerHis-) from the fusion protein remained on the N-terminus following thrombin cleavage. Purified FIH was buffer-exchanged into 50 mM HEPES (pH 7.00). The purity (>95%) of each variant was assessed by sodium dodecyl sulfate—polyacrylamide gel electrophoresis.

Steady-State Kinetics Assays. All assays used saturating concentrations of FeSO<sub>4</sub> (25  $\mu$ M) and ascorbate (2 mM) and an ambient O<sub>2</sub> concentration (217  $\mu$ M at 37.0 °C) and were performed in 50 mM HEPES (pH 7.00) at 37.0 °C unless specifically noted otherwise. DTT (200  $\mu$ M) was added to assays for FIH-Gln<sup>239</sup>  $\rightarrow$  His and FIH-Gln<sup>239</sup>  $\rightarrow$  Glu when these variants were tested in D<sub>2</sub>O, as nonlinear progress curves were observed otherwise. Assays in which CTAD was the varied substrate (from 15 to 300  $\mu$ M) utilized a saturating  $\alpha$ KG concentration (500  $\mu$ M). Assays with  $\alpha$ KG as the varied substrate (from 2.5 to 100  $\mu$ M) utilized a fixed CTAD concentration of 100  $\mu$ M [~ $K_{M(CTAD)}$ ] to conserve on the use of the peptide. Assay reagents were mixed and incubated for 2 min at 37.0 °C before the addition of enzyme ( $[E]_T = 1.5-10$  $\mu$ M). Reaction aliquots (5  $\mu$ L) were quenched with a 75% acetonitrile/0.2% TFA mixture (20 µL) saturated with 3,5dimethoxy-4-hydroxycinnamic acid and analyzed for peptide hydroxylation using a Bruker Daltonics Omniflex matrixassisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) instrument. Initial rates were determined from five to seven quenched time points (0 to ~15% fractional conversion). The nonlinear least-squares fitting of initial rate data to the Michaelis-Menten equation yielded the apparent steady-state rate constants,  $k_{cat}$  and  $k_{cat}$ /  $K_{\rm M}$ . All assays were replicated a minimum of three times.

**Solvent Kinetic Isotope Effects (SKIEs).** Steady-state assays for SKIEs were performed under the same conditions reported above, with the exception that all reagents were prepared in  $D_2O$ . Deuterium oxide (D, 99.9%) was purchased

from Cambridge Isotope Laboratories (Andover, MA) and used as received. Working FIH stock solutions were made by diluting high-concentration stocks from H<sub>2</sub>O into D<sub>2</sub>O containing 50 mM HEPES (pD 7.00). Assays were performed in 50 mM HEPES (pD 7.00), with a final D<sub>2</sub>O percentage estimated to be 96%. SKIEs were calculated from the direct comparison of kinetic parameters observed in buffers containing H<sub>2</sub>O and D<sub>2</sub>O; e.g.,  ${}^{D_2O}k_{cat} = k_{cat(H_2O)}/k_{cat(D_2O)}$ .

Succinate Quantification. The coupling between the two half-reactions was determined by monitoring the production of succinate and CTAD<sup>OH</sup> concentrations in several quench points from a common reaction. Reactions of  $\alpha KG$  (500  $\mu M$ ), FeSO<sub>4</sub> (25  $\mu$ M), CTAD (350  $\mu$ M), and FIH (5–10  $\mu$ M) were conducted at 37.0 °C and analyzed similarly using previously reported procedures.<sup>25,40,47</sup> As HEPES interfered with the succinate analysis, the reaction buffer consisted of 50 mM Tris (pL 7.00). A Hamilton PRP-X300 anion exclusion column was used to separate the succinate produced from the quenched reactions, and UV detection at 210 nm was used to determine the succinate concentration. Using aliquots from the same quenched assay, a Bruker Daltonics Omniflex MALDI-TOF MS was used to determine the CTAD<sup>OH</sup> concentration. The coupling ratio (C) was determined by taking the ratio of the rate of succinate formation and the rate of CTAD<sup>OH</sup> formation from matched time points.

**Fluorescence Spectroscopy.** The FIH–CTAD binding constants were measured through quenching of the intrinsic tryptophan fluorescence of (Co +  $\alpha$ KG)FIH upon CTAD binding at room temperature (~20 °C). The fluorescence cuvette contained FIH (1.5  $\mu$ M), CoSO<sub>4</sub> (25  $\mu$ M),  $\alpha$ KG (500  $\mu$ M), and 50 mM HEPES (pH 7.05). This solution was titrated with 50 mM HEPES (pH 7.05) containing CTAD (1 mM), FIH (1.5  $\mu$ M), CoSO<sub>4</sub> (25  $\mu$ M), and  $\alpha$ KG (500  $\mu$ M). All titrations were performed aerobically. After each addition of titrant, samples were gently mixed and allowed to equilibrate for 5 min before being excited at 295 nm. The fluorescence intensities at 330 nm were plotted versus the total CTAD concentration and fit using eq 1

$$\frac{I - I_0}{I_f - I_0} = \left[ [E] + [S] + K_D - \sqrt{([E] + [S] + K_D)^2 - 4[E][S]n} \right] / \left( 2[E] \right)$$
(1)

where *I* is the measured fluorescence intensity, [E] is the protein concentration, [S] is the total CTAD concentration, *n* is the number of binding sites, and  $K_D$  is the binding affinity. The initial intensity ( $I_0$ ) and final intensity ( $I_f$ ) were obtained from measured spectra.

## RESULTS

Variants of FIH-Gln<sup>239</sup> were used to test the effect of target residue positioning on substrate hydroxylation in FIH. The variants were designed to vary hydrogen bonding potential  $(Gln^{239} \rightarrow Glu \text{ and } Gln^{239} \rightarrow His)$  and cavity size  $(Gln^{239} \rightarrow$ Ala,  $Gln^{239} \rightarrow Asn$ , and  $Gln^{239} \rightarrow Leu$ ) in the target residue pocket of FIH. The  $Gln^{239}$  variants were kinetically characterized in the steady state with CTAD as the varied substrate, giving the apparent rate constants  $k_{cat}$  and  $k_{cat}/$  $K_{M(CTAD)}$ . The kinetic characterization revealed significantly diminished rate constants for turnover, leading us to determine the binding affinity of CTAD as well as the coupling ratio of the two half-reactions for each point mutant.

Kinetic Characterization of  $Gln^{239} \rightarrow X$  Variants. We hypothesized the positioning of CTAD-Asn<sup>803</sup> by FIH-Gln<sup>239</sup> was necessary to support turnover and therefore focused our studies on steady-state characterization by monitoring CTAD<sup>OH</sup> formation via MALDI-TOF. Although  $O_2$  uptake was the first method that we considered, the slow turnover for FIH makes high-precision kinetic determinations by this method challenging. Assays using fixed concentrations of  $\alpha$ KG (500  $\mu$ M) and O<sub>2</sub> (217  $\mu$ M) and varied concentrations of CTAD  $(15-300 \mu M)$  were used to measure initial rates. which where then fit to the Michaelis-Menten equation to obtain the apparent steady-state rate constants,  $k_{cat}$  and  $k_{cat}$ /  $K_{M(CTAD)}$ . The Michaelis constant for  $\alpha KG$  was determined for each variant  $[K_{M(\alpha KG)} = 4-7 \ \mu M]$ , which was slightly lower than that for WT-FIH [ $K_{M(\alpha KG)} = 16 \ \mu M$ ]. Because of the O<sub>2</sub> concentration is subsaturating, the apparent  $k_{cat}$  encompasses all steps after CTAD binding, including those involved in O2 binding and activation. All of the  $Gln^{239} \rightarrow X$  variants exhibited a significant decrease in  $k_{\rm cat}$  (Figure 2). The  ${\rm Gln}^{239} \rightarrow {\rm Ala}~(k_{\rm cat}$ 



**Figure 2.** Steady-state kinetics of Q239A in H<sub>2</sub>O. FIH (1.5  $\mu$ M), ascorbate (2 mM),  $\alpha$ KG (500  $\mu$ M), FeSO<sub>4</sub> (25  $\mu$ M), and CTAD (0–300  $\mu$ M) were in 50 mM HEPES (pH 7.00). The inset shows the steady-state kinetics of Q239N ( $\blacktriangle$ ),Q239H ( $\blacksquare$ ), and Q239E ( $\diamondsuit$ ) in H<sub>2</sub>O. FIH (1.5–30  $\mu$ M), ascorbate (2 mM),  $\alpha$ KG (500  $\mu$ M), FeSO<sub>4</sub> (25  $\mu$ M), and CTAD (0–300  $\mu$ M) were in 50 mM HEPES (pH 7.00).

= 1.27 ± 0.10 min<sup>-1</sup>) variant was most active, as the  $k_{\rm cat}$  decreased 20-fold relative to that of WT-FIH, whereas the  $k_{\rm cat}$  for  ${\rm Gln}^{239} \rightarrow {\rm Asn} (0.14 \pm 0.02 {\rm min}^{-1})$  decreased 200-fold. The  $k_{\rm cat}$  for variants capable of one-point hydrogen bonding decreased >1200-fold:  ${\rm Gln}^{239} \rightarrow {\rm His} (0.023 \pm 0.003 {\rm min}^{-1})$  and  ${\rm Gln}^{239} \rightarrow {\rm Glu} (0.024 \pm 0.002 {\rm min}^{-1})$ . We were unable to observe hydroxylation from the  ${\rm Gln}^{239} \rightarrow {\rm Leu}$  variant.

Steps from CTAD binding through the first irreversible step (decarboxylation) comprise  $k_{\rm cat}/K_{\rm M(CTAD)}$  (Scheme 2). The effect of each point variant on  $k_{\rm cat}/K_{\rm M(CTAD)}$  was nearly identical to their effect on  $k_{\rm cat}$ , indicating that the variants affected a step that was separate from CTAD binding.

We tested the activity of FIH-Gln<sup>239</sup>  $\rightarrow$  Asn using a 19-mer CTAD peptide containing the complementary CTAD-Asn<sup>803</sup>  $\rightarrow$  Gln point mutation, which switched the residues at this interface. This switch mutation was designed to restore the bulk

and hydrogen bonds observed between WT-FIH and WT-CTAD. However, the activity level was below our detection limit (0.002 min<sup>-1</sup>), as hydroxylated CTAD-Asn<sup>803</sup>  $\rightarrow$  Gln was not detected upon being incubated with FIH-Gln<sup>239</sup>  $\rightarrow$  Asn. WT-FIH was similarly unreactive toward this variant CTAD, as WT-FIH hydroxylated the 19-mer WT-CTAD with an appreciable rate, but did not hydroxylate the variant CTAD (Table 1).

**Binding Affinity of CTAD for Gln<sup>239</sup>**  $\rightarrow$  **X Variants.** The binding affinity of each FIH variant for CTAD was measured by titration using the intrinsic tryptophan fluorescence of FIH. A solution containing CTAD (1 mM) was titrated into a solution containing FIH (1.5  $\mu$ M) while the fluorescence at 330 nm was monitored ( $\lambda_{ex} = 295$  nm); both solutions were anaerobic and contained CoSO<sub>4</sub> (25  $\mu$ M) and  $\alpha$ KG (500  $\mu$ M). The change in fluorescence intensity (330 nm) was plotted as a function of CTAD concentration and fit to eq 1. The experimentally determined  $K_D$  for each point mutant (Table 2) was similar to that of WT-FIH (78  $\pm$  7  $\mu$ M), indicating the thermodynamics of CTAD binding was not affected by point mutation.

**Uncoupled Turnover in the Gin**<sup>239</sup>  $\rightarrow$  X Variants. The kinetic parameters of the Gln<sup>239</sup>  $\rightarrow$  X mutations led us to explore the coupling of O<sub>2</sub> activation to substrate hydroxylation. We hypothesized that if the conformational state of CTAD-Asn<sup>803</sup> were incorrect for HAT, then the two half-reactions would uncouple to produce more succinate than hydroxylated product (CTAD<sup>OH</sup>). Quenched aliquots from reaction mixtures containing saturating concentrations of  $\alpha KG$  (500  $\mu$ M) and CTAD (350  $\mu$ M) in 50 mM Tris (pH 7.00) were analyzed for CTAD<sup>OH</sup> via MALDI-TOF MS and succinate via HPLC. Tris buffer was used for these assays to minimize the background signal in the HPLC chromatograms that arose due to buffer components.

The coupling values for the  $Gln^{239} \rightarrow X$  (X = Ala, Asn, Glu, and His) variants were obtained by taking the ratio of the rates of formation for succinate and  $CTAD^{OH}$ . Variants produced three to five succinates per equivalent of  $CTAD^{OH}$ ; succinate formation was observed for the  $Gln^{239} \rightarrow Leu$  variant  $[k_{obs(suc)} =$ 0.08 min<sup>-1</sup>], indicating O<sub>2</sub> activation occurred even though CTAD hydroxylation was not detected for this variant (Table 3). This uncoupling is similar to the values found previously for second-coordination sphere variants of FIH.<sup>40</sup>

The coupling of WT,  $\operatorname{Gln}^{239} \to \operatorname{Ala}$ , and  $\operatorname{Gln}^{239} \to \operatorname{Asn}$  in deuterated buffer was used to determine if the coupling ratio changed between protonated and deuterated buffers. The coupling for WT FIH in H<sub>2</sub>O ( $C = 1.0 \pm 0.1$ ) and D<sub>2</sub>O (C = $1.0 \pm 0.1$ ) was in agreement with our previous work,<sup>25</sup> showing WT remains tightly coupled under all tested conditions. However, the coupling ratio in D<sub>2</sub>O for  $\operatorname{Gln}^{239} \to \operatorname{Ala} (C =$  $1.4 \pm 0.2$ ) and  $\operatorname{Gln}^{239} \to \operatorname{Asn} (C = 2.2 \pm 0.2)$  approached unity, indicating that solvent deuteration led to more tightly coupled turnover for these variants.

**Solvent Kinetic Isotope Effects (SKIEs).** SKIEs on both  $k_{\text{cat}}$  and  $k_{\text{cat}}/K_{\text{M(CTAD)}}$  were used to test the importance of solvent-dependent steps during turnover. Initial rates from steady-state assays using saturating  $\alpha$ KG concentrations (500  $\mu$ M), ambient O<sub>2</sub> concentrations (217  $\mu$ M), and varied concentrations of CTAD (15–300  $\mu$ M) were fit to the Michaelis–Menten equation (Figure 3). Turnover was faster in D<sub>2</sub>O with both WT-FIH and each variant, leading to an inverse SKIE on  $k_{\text{cat}}$  and  $k_{\text{cat}}/K_{\text{M(CTAD)}}$  (Table 4). However, these SKIEs must be considered in the context of the solvent-dependent uncoupling observed for the variants.<sup>51</sup>

# Scheme 2. Minimal Chemical Scheme for Uncoupling



## Table 1. Initial Rates for 19-mer Peptides CTAD and CTAD-N803Q<sup>a</sup>

	initial rate (min <sup>-1</sup> )				
	WT-CTAD	CTAD-N803Q			
WT	0.70	< 0.005 <sup>b</sup>			
Q239N	<0.005	< 0.005 <sup>b</sup>			

<sup>*a*</sup>Assays contained ascorbate (2 mM),  $\alpha$ KG (500  $\mu$ M), FeSO<sub>4</sub> (25  $\mu$ M), and 19-mer CTAD (400  $\mu$ M) in 50 mM HEPES (pH 7.00) at 37.0 °C. The CTAD peptide used contained 19 residues. <sup>*b*</sup>No activity detected; estimated detection limit, if active.

# DISCUSSION

The ordered sequential consensus mechanism for  $\alpha$ KG oxygenases leads to coupled turnover when primary substrate binding stimulates reactivity toward O<sub>2</sub>, a phenomenon termed substrate-induced activity enhancement,<sup>52</sup> priming,<sup>53</sup> or triggering<sup>54</sup> by different groups. As primary substrate does not directly bind to the Fe(II), altered local contacts within the active site likely stimulate O<sub>2</sub> activation. Although the idea of stimulated O<sub>2</sub> activation refers to the empirical observation of increased turnover rates induced by substrate binding, the dominant model used to explain this focuses on aquo release, which creates an open coordination site for O<sub>2</sub> binding.<sup>39</sup> In our opinion, broader changes within the active site are correlated with this effect, such as the position of the primary substrate.

# Table 3. Coupling of Succinate and $CTAD^{OH}$ Concentrations for FIH and Variants<sup>*a*</sup>

	$k_{\rm obs(H_2O)}$ ([succinate] min <sup>-1</sup> [FIH] <sup>-1</sup> )	$C_{\rm H_2O}{}^b$	$C_{D_2O}{}^b$
WT	$28 \pm 2$	$1.0 \pm 0.1$	$1.0 \pm 0.1$
Q239A	$5.5 \pm 0.3$	$4 \pm 1$	$1.4 \pm 0.2$
Q239N	$0.49 \pm 0.08$	$3.3 \pm 0.3$	$2.2\pm0.2$
Q239H	$0.06 \pm 0.02$	$3 \pm 1$	$ND^{c}$
Q239E	$0.07 \pm 0.03$	$5 \pm 1$	$ND^{c}$
Q239L	$0.08 \pm 0.02$	$ND^{c}$	$ND^{c}$

<sup>*a*</sup>Reaction mixtures contained FIH (5–10  $\mu$ M),  $\alpha$ KG (500  $\mu$ M), FeSO<sub>4</sub> (25  $\mu$ M), and CTAD (350  $\mu$ M) in 50 mM Tris (pL 7.00) at 37 °C. <sup>*b*</sup>C = (moles of succinate per minute)/(moles of CTAD<sup>OH</sup> per minute). <sup>*c*</sup>Not determined.

FIH is notable in that enzyme–substrate contacts are quite extensive because the substrate is a large peptide (CTAD), with the target residue positioned above the Fe by a two-point hydrogen bond to the side chain of an anchoring residue, FIH-Gln<sup>239,14,55</sup> This study varied the sterics and H-bonding potential of this anchor residue to test its role in hydroxylating CTAD-Asn<sup>803</sup>.

**CTAD Hydroxylation Is Slowed by Gln<sup>239</sup> Variants.** Each of the  $Gln^{239} \rightarrow X$  variants (X = Ala, Asn, Glu, His, or Leu) altered the hydrogen bond potential and/or bulk of the target residue pocket, disrupting the positioning of the target residue. This incorrect positioning could have impacted any one of several steps within the kinetic mechanism, which may

### Table 2. Apparent Kinetic Parameters for FIH and Its Variants<sup>a</sup>

	$k_{\rm cat} \ ({\rm min}^{-1})^b$	$k_{\rm cat}/K_{ m M(CTAD)} \; (\mu M^{-1} \; { m min}^{-1})^b$	$K_{\mathrm{M(CTAD)}} (\mu \mathrm{M})^{b}$	$K_{\rm D(CTAD)} \ (\mu { m M})^c$	$K_{\mathrm{M}(lpha\mathrm{KG})} \; (\mu\mathrm{M})^d$
WT	$30 \pm 2.5^{e}$	$0.4 \pm 0.1^{e}$	$70 \pm 20^{e}$	$78 \pm 7^{f}$	$16 \pm 3.0$
Q239A	$1.3 \pm 0.10$	$0.021 \pm 0.002$	$61 \pm 10$	$100 \pm 16$	$5.0 \pm 0.5$
Q239N	$0.14 \pm 0.02$	$2.0 \times 10^{-3} \pm 8 \times 10^{-4}$	$74 \pm 30$	$98 \pm 10$	$4.0 \pm 0.4$
Q239H	$0.023 \pm 0.003$	$(3.4 \pm 1) \times 10^{-4}$	$68 \pm 18$	64 ± 14	$7.0 \pm 1.4$
Q239E	$0.024 \pm 0.002$	$3.4 \times 10^{-4} \pm 7 \times 10^{-5}$	$71 \pm 10$	$75 \pm 15$	$4.7 \pm 2.0$
Q239L	< 0.005 <sup>g</sup>	$<8 \times 10^{-5g}$	$ND^{h}$	$80 \pm 8$	$ND^{h}$

<sup>*a*</sup>In 50 mM HEPES (pH 7.00) at 37.0 °C. <sup>*b*</sup>Assays in which CTAD was the varied substrate, in ascorbate (2 mM),  $\alpha$ KG (500  $\mu$ M), FeSO<sub>4</sub> (25  $\mu$ M), and CTAD (0–300  $\mu$ M). <sup>*c*</sup>Determined using intrinsic tryptophan fluorescence with Co-substituted enzyme. <sup>*d*</sup>Assays in which  $\alpha$ KG was the varied substrate, in ascorbate (2 mM),  $\alpha$ KG (2–200  $\mu$ M), FeSO<sub>4</sub> (25  $\mu$ M), and CTAD (100  $\mu$ M). <sup>*c*</sup>From ref 25. <sup>*f*</sup>From ref 30. <sup>*g*</sup>No activity detected; estimated detection limits as reported. <sup>*h*</sup>Not determined.



**Figure 3.** Steady-state kinetics of Q239A in H<sub>2</sub>O ( $\bullet$ ) and 96% D<sub>2</sub>O ( $\blacksquare$ ) buffers. FIH (1.5–30  $\mu$ M), ascorbate (2 mM),  $\alpha$ KG (500  $\mu$ M), FeSO<sub>4</sub> (25  $\mu$ M), and CTAD (0–300  $\mu$ M) were in 50 mM HEPES (pL 7.00).

be distinguished through analysis of steady-state kinetic parameters and coupling ratios. The significant reduction in  $k_{\rm cat}$  and  $k_{\rm cat}/K_{\rm M(CTAD)}$  relative to those of WT-FIH indicated that the anchor residue played a prominent role in supporting turnover. Keeping in mind the observation that the binding affinity of CTAD was unchanged from that of WT-FIH (Table 2), we are led to conclude that the predominant role of FIH-Gln<sup>239</sup> is to position substrate for a chemical step rather than to bind CTAD.

Although it may seem surprising that the anchor residue FIH-Gln<sup>239</sup> contributes very little to the CTAD binding affinity, this is consistent with prior studies of CTAD variants. As the length of the CTAD has been shown to have a significant affect on the  $K_{M}$ <sup>56</sup> and the binding affinity of WT-FIH for CTAD is indistinguishable from the Michaelis constant, it appears that the dominant factor in CTAD binding is the surface contact with FIH, with only minor contributions from the target residue pocket. Alanine scanning point mutagenesis of CTAD revealed that CTAD-Val<sup>802</sup> was the most significant residue for CTAD binding, with a 2-fold increase in the  $K_{M(CTAD)}$  for the CTAD-Val<sup>802</sup>  $\rightarrow$  Ala variant.<sup>57</sup> Molecular dynamics studies suggested that this mutation led to reorientation of Asn<sup>803</sup>, perhaps because of disruption of the tight turn conformation in residues 801-803 of CTAD. Further support for a minimal impact of FIH-Gln<sup>239</sup> on CTAD binding is the observation that FIH hydroxylates substrates with target residues other than

asparagine.<sup>58,59</sup> The structural features of these substrates suggest the overall contact between FIH and the CTAD peptide is important in determining substrate binding to FIH.<sup>59,60</sup>

**Inverse SKIEs and Coupling.** We recently reported inverse SKIEs for WT FIH, on both  $k_{cat}$  and  $k_{cat}/K_{M(CTAD)}$ .<sup>25</sup> This was due to the isotopically sensitive metal—aquo fractionation prior to a rate-limiting step for WT-FIH. Importantly, WT-FIH exhibited fully coupled turnover, such that O<sub>2</sub> activation always led to substrate hydroxylation. Consequently, it was deduced that the rate-limiting step for  $k_{cat}$  and  $k_{cat}/K_{M(CTAD)}$  was an irreversible step immediately after aquo release. This step is depicted as the oxidative decarboxylation of  $\alpha$ KG in Scheme 1.

For each of the  $Gln^{239} \rightarrow X$  variants, inverse SKIEs were measured on both  $k_{cat}$  and  $k_{cat}/K_{M(CTAD)}$  when determined from the rate of  $CTAD^{OH}$  formation (Table 4). Although the SKIE data resembled those reported for WT-FIH, turnover for these variants was significantly uncoupled, which precluded the use of SKIEs to diagnose rate-limiting steps in the steady state. Nevertheless, uncoupling in the variants depended on solvent isotopic composition (Table 3), suggesting that the ferryl intermediate could form even when CTAD was improperly positioned. The fact that *C* approached unity in D<sub>2</sub>O for these variants suggested that the main effect of the  $Gln^{239} \rightarrow X$ change was to perturb the hydroxylation step.

Sterics and H-Bonding Impact Substrate Hydroxylation. A simple model to explain how the target residue pocket impacts productive turnover is one in which multiple conformational states of the target residue are adopted but only one conformation supports hydroxylation. X-ray crystal structures of  $(M+\alpha KG)FIH$  bound to CTAD<sup>14</sup> or Notchderived peptides<sup>55</sup> revealed that the target residue adopted a specific rotameric conformation, with a side chain torsional angle (HN- $C_{\alpha}$ - $C_{\beta}$ - $C_{\gamma}$ ) of -71°. This is observed for both Notch target residues Notch-Asn<sup>210</sup> and Notch-Asn<sup>1945</sup> [Protein Data Bank (PDB) entries 3P3P and 3P3N, respectively]. As a good deal of flexibility near Gln<sup>239</sup> was observed crystallographically for  $(Fe+\alpha KG)FIH$  when CTAD was absent (PDB entry 1MZF),48 changing the hydrogen bonding potential and packing density of this anchor residue should alter the target residue position above the Fe(II). The significant reduction in catalytic efficiency for each point mutant strongly suggests that the major role of FIH-Gln<sup>239</sup> is to stabilize the proper rotamer of CTAD-Asn<sup>803</sup> that can undergo hydroxylation during turnover.

The kinetic data further suggest that packing near the target residue may also impact  $O_2$  activation in FIH. The overall trend in the kinetic parameters measured by coupled turnover (Table 2) was dominated by bulk, as the kinetic parameters for the

Table 4	Annarent	Kinetic	Parameters	in	D.O	and	SKIFe	for	FIH	and	Ite	Variant	e a
Table 4.	Apparent	Kinetic	Parameters	m	$D_2O$	and	SKIES	101	гіп	and	Its	variant	S

	$k_{\rm cat} \ ({\rm min}^{-1})^b$	$k_{ m cat}/K_{ m M(CTAD)}~(\mu { m M}^{-1}~{ m min}^{-1})^b$	$^{D_2O}k_{cat}^{c}$	${}^{\mathrm{D_2O}}k_{\mathrm{cat}}/K_{\mathrm{M(CTAD)}}{}^d$
$WT^{e}$	$59 \pm 2$	$1.09 \pm 0.11$	$0.51 \pm 0.07$	$0.40 \pm 0.07$
Q239A	$2.55 \pm 0.21$	$0.044 \pm 0.011$	$0.50 \pm 0.05$	$0.48 \pm 0.15$
Q239N	$0.27 \pm 0.02$	$0.005 \pm 0.001$	$0.50 \pm 0.06$	$0.41 \pm 0.18$
Q239H	$0.050 \pm 0.003$	$2.0 \times 10^{-3} \pm 8 \times 10^{-4}$	$0.46 \pm 0.07$	$0.17 \pm 0.06$
Q239E	$0.046 \pm 0.002$	$(8 \pm 3) \times 10^{-4}$	$0.52 \pm 0.05$	$0.41 \pm 0.16$
Q239L	$\mathrm{ND}^{f}$	$\mathrm{ND}^{f}$	$ND^{f}$	$ND^{f}$

<sup>*a*</sup>In 50 mM HEPES (pD 7.00) at 37.0 °C. <sup>*b*</sup>Determined from assays with CTAD as the varied substrate, in ascorbate (2 mM),  $\alpha$ KG (500  $\mu$ M), FeSO<sub>4</sub> (25  $\mu$ M), and CTAD (0–250  $\mu$ M);  $\chi_{D_2O}$  = 0.96. <sup>*c*D\_2O</sup> $k_{cat} = k_{cat(H_2O)}/k_{cat(D_2O)}$ . <sup>*d*D\_2O</sup> $k_{cat}/K_{M(CTAD)} = [k_{cat}/K_{M(CTAD)} \text{ in } H_2O]/[k_{cat}/K_{M(CTAD)} \text{ in } D_2O]$ . <sup>*c*From ref 25. <sup>*f*</sup>Not determined.</sup>

 $\operatorname{Gln}^{239} \to X$  point variants decreased monotonically in a series:  $X = (\operatorname{Ala} > \operatorname{Asn} > \operatorname{Glu}$  and His  $\gg$  Leu). As the kinetic parameters of the variants listed in Table 2 are functions of all steps leading to CTAD hydroxylation, it is not possible to separately identify the impact of the variants on O<sub>2</sub> activation. However, the coupling data directly measured succinate production (Table 4), which reports directly on O<sub>2</sub> activation. The rates of succinate production clearly showed that each variant produced succinate much more slowly that WT-FIH, suggesting that O<sub>2</sub> activation was slowed in these variants. As the packing about CTAD-Asn<sup>803</sup> is quite tight in WT-FIH,<sup>14</sup> it is possible that the Gln<sup>239</sup>  $\rightarrow$  X variants excluded CTAD-Asn<sup>803</sup> from the proper conformation, which could impede access of O<sub>2</sub> to the Fe(II) as well as hydroxylation by the putative ferryl intermediate (Scheme 2).

# CONCLUSION

This work establishes that proper positioning of the primary substrate (CTAD) is required to support coupled turnover by FIH. We conclude that proper positioning of substrate is crucial for the hydroxylation of CTAD as well as for stimulation of  $O_2$  activation. Mispositioned CTAD impedes  $O_2$  activation, suggesting that the environment near the Fe(II) cofactor plays a marked role in  $O_2$  activation.

# ASSOCIATED CONTENT

#### **S** Supporting Information

Control experiments showing the thermal stability of the  $Gln^{239}$   $\rightarrow$  X variant and intrinsic tryptophan fluorescence titrations with CTAD. This material is available free of charge via the Internet at http://pubs.acs.org.

# AUTHOR INFORMATION

## **Corresponding Author**

\*Department of Chemistry, University of Massachusetts, Amherst, MA 01003. E-mail: mknapp@chem.umass.edu. Phone: (413) 545-4001. Fax: (413) 545-4490.

#### Funding

Research reported in this publication was supported by National Institutes of Health Grant R01-GM077413 and National Institutes of Health Chemistry-Biology Interface Predoctoral Training Fellowship T32-GM008515.

#### Notes

The authors declare no competing financial interest.

#### ACKNOWLEDGMENTS

We thank Dr. Evren Saban for the purification of the  $Gln^{239} \rightarrow$  Asn variant and the late Professor Robert Weiss for the use of his differential scanning calorimeter.

## ABBREVIATIONS

 $\alpha$ KG,  $\alpha$ -ketoglutarate; CAS, clavaminate synthase; CD, circular dichroism; CREBP, cAMP response element-binding protein; CTAD, C-terminal transactivation domain; DFT, density functional theory; DTT, dithiothreitol; FIH, factor-inhibiting HIF; HAT, hydrogen atom transfer; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; HIF, hypoxia inducible factor-1 $\alpha$ ; MCD, magnetic circular dichroism; NOG, *N*-oxalyl glycine; P4H, prolyl-4-hydroxylase; SKIE, solvent kinetic isotope effect; TauD, taurine dioxygenase.

# REFERENCES

(1) Hausinger, R. P. (2004) Fe(II)/ $\alpha$ -Ketoglutarate-dependent hydroxylases and related enzymes. *Crit. Rev. Biochem. Mol. Biol.* 39, 21–68.

(2) Purpero, V., and Moran, G. R. (2007) The diverse and pervasive chemistries of the  $\alpha$ -keto acid dependent enzymes. *JBIC*, *J. Biol. Inorg. Chem.* 12, 587–601.

(3) Jaakkola, P., Mole, D. R., Tian, Y. M., Wilson, M. I., Gielbert, J., Gaskell, S. J., von Kriegsheim, A., Hebestreit, H. F., Mukherji, M., Schofield, C. J., Maxwell, P. H., Pugh, C. W., and Ratcliffe, P. J. (2001) Targeting of HIF- $\alpha$  to the von Hippel-Lindau ubiquitylation complex by O<sub>2</sub>-regulated prolyl hydroxylation. *Science* 292, 468–472.

(4) Lando, D., Peet, D. J., Whelan, D. A., Gorman, J. J., and Whitelaw, M. L. (2002) Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. *Science* 295, 858–861.

(5) Duncan, T., Trewick, S. C., Koivisto, P., Bates, P. A., Lindahl, T., and Sedgwick, B. (2002) Reversal of DNA alkylation damage by two human dioxygenases. *Proc. Natl. Acad. Sci. U.S.A.* 99, 16660–16665.

(6) Trewick, S. C., Henshaw, T. F., Hausinger, R. P., Lindahl, T., and Sedgwick, B. (2002) Oxidative demethylation by *Escherichia coli* AlkB directly reverts DNA base damage. *Nature 419*, 174–178.

(7) Tsukada, Y., Fang, J., Erdjument-Bromage, H., Warren, M. E., Borchers, C. H., Tempst, P., and Zhang, Y. (2006) Histone demethylation by a family of JmjC domain-containing proteins. *Nature* 439, 811–816.

(8) Zheng, G., Dahl, J. A., Niu, Y., Fedorcsak, P., Huang, C.-M., Li, C. J., Vagbo, C. B., Shi, Y., Wang, W.-L., Song, S.-H., Lu, Z., Bosmans, R. P. G., Dai, Q., Hao, Y.-J., Yang, X., Zhao, W.-M., Tong, W.-M., Wang, X.-J., Bogdan, F., Furu, K., Fu, Y., Jia, G., Zhao, X., Liu, J., Krokan, H. E., Klungland, A., Yang, Y.-G., and He, C. (2013) ALKBH5 Is a Mammalian RNA Demethylase that Impacts RNA Metabolism and Mouse Fertility. *Mol. Cell* 49, 18–29.

(9) Jia, G., Fu, Y., Zhao, X., Dai, Q., Zheng, G., Yang, Y., Yi, C., Lindahl, T., Pan, T., Yang, Y.-G., and He, C. (2011) N6-Methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. *Nat. Chem. Biol.* 7, 885–887.

(10) Rose, N. R., McDonough, M. A., King, O. N. F., Kawamura, A., and Schofield, C. J. (2011) Inhibition of 2-oxoglutarate dependent oxygenases. *Chem. Soc. Rev.* 40, 4364–4397.

(11) Loenarz, C., and Schofield, C. J. (2011) Physiological and biochemical aspects of hydroxylations and demethylations catalyzed by human 2-oxoglutarate oxygenases. *Trends Biochem. Sci.* 36, 7–18.

(12) Holme, E. (1975) Kinetic study of thymine 7-hydroxylase from *Neurospora crassa*. *Biochemistry* 14, 4999–5003.

(13) De Carolis, E., and De Luca, V. (1993) Purification, characterization, and kinetic analysis of a 2-oxoglutarate-dependent dioxygenase involved in vindoline biosynthesis from *Catharanthus* roseus. J. Biol. Chem. 268, 5504–5511.

(14) Elkins, J. M., Hewitson, K. S., McNeill, L. A., Seibel, J. F., Schlemminger, I., Pugh, C. W., Ratcliffe, P. J., and Schofield, C. J. (2003) Structure of factor-inhibiting hypoxia-inducible factor (HIF) reveals mechanism of oxidative modification of HIF-1 $\alpha$ . J. Biol. Chem. 278, 1802–1806.

(15) Ozer, A., and Bruick, R. K. (2007) Non-heme dioxygenases: Cellular sensors and regulators jelly rolled into one? *Nat. Chem. Biol. 3*, 144–153.

(16) Semenza, G. L. (2004) Hydroxylation of HIF-1: Oxygen sensing at the molecular level. *Physiology* 19, 176–182.

(17) Iyer, N. V., Kotch, L. E., Agani, F., Leung, S. W., Laughner, E., Wenger, R. H., Gassmann, M., Gearhart, J. D., Lawler, A. M., Yu, A. Y., and Semenza, G. L. (1998) Cellular and developmental control of  $O_2$  homeostasis by hypoxia-inducible factor 1 $\alpha$ . *Genes Dev. 12*, 149–162. (18) Semenza, G. L. (2003) Targeting HIF-1 for cancer therapy. *Nat. Rev. Cancer 3*, 721–32.

(19) Metzen, E., and Ratcliffe, P. J. (2004) HIF hydroxylation and cellular oxygen sensing. *Biol. Chem.* 385, 223–230.

(20) McNeill, L. A., Hewitson, K. S., Claridge, T. D., Seibel, J. F., Horsfall, L. E., and Schofield, C. J. (2002) Hypoxia-inducible factor asparaginyl hydroxylase (FIH-1) catalyses hydroxylation at the  $\beta$ carbon of asparagine-803. *Biochem. J.* 367, 571–575.

(21) Lando, D., Peet, D. J., Gorman, J. J., Whelan, D. A., Whitelaw, M. L., and Bruick, R. K. (2002) FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. *Genes Dev.* 16, 1466–1471.

(22) Price, J. C., Barr, E. W., Hoffart, L. M., Krebs, C., and Bollinger, J. M. (2005) Kinetic dissection of the catalytic mechanism of taurine: $\alpha$ -ketoglutarate dioxygenase (TauD) from *Escherichia coli*. *Biochemistry* 44, 8138–8147.

(23) Salowe, S. P., Marsh, E. N., and Townsend, C. A. (1990) Purification and characterization of clavaminate synthase from *Streptomyces clavuligerus*: An unusual oxidative enzyme in natural product biosynthesis. *Biochemistry 29*, 6499–6508.

(24) Thornburg, L. D., Lai, M. T., Wishnok, J. S., and Stubbe, J. (1993) A non-heme iron protein with heme tendencies: An investigation of the substrate specificity of thymine hydroxylase. *Biochemistry* 32, 14023–14033.

(25) Hangasky, J. A., Saban, E., and Knapp, M. J. (2013) Inverse Solvent Isotope Effects Arising from Substrate Triggering in the Factor Inhibiting Hypoxia Inducible Factor. *Biochemistry* 52, 1594–1602.

(26) Zhou, J., Kelly, W. L., Bachmann, B. O., Gunsior, M., Townsend, C. A., and Solomon, E. I. (2001) Spectroscopic studies of substrate interactions with clavaminate synthase 2, a multifunctional  $\alpha$ -KG-dependent non-heme iron enzyme: Correlation with mechanisms and reactivities. J. Am. Chem. Soc. 123, 7388–7398.

(27) Zhou, J., Gunsior, M., Bachmann, B. O., Townsend, C. A., and Solomon, E. I. (1998) Substrate Binding to the  $\alpha$ -Ketoglutarate-Dependent Non-Heme Iron Enzyme Clavaminate Synthase 2: Coupling Mechanism of Oxidative Decarboxylation and Hydroxylation. J. Am. Chem. Soc. 120, 13539–13540.

(28) Pavel, E. G., Zhou, J., Busby, R. W., Gunsior, M., Townsend, C. A., and Solomon, E. I. (1998) Circular dichroism and magnetic circular dichroism spectroscopic studies of the non-heme ferrous active site in clavaminate synthase and its interaction with  $\alpha$ -ketoglutarate cosubstrate. J. Am. Chem. Soc. 120, 743–753.

(29) Whiting, A. K., Que, L., Saari, R. E., Hausinger, R. P., Fredrick, M. A., and McCracken, J. (1997) Metal Coordination Environment of a Cu(II)-Substituted  $\alpha$ -Keto Acid-Dependent Dioxygenase That Degrades the Herbicide 2,4-D. J. Am. Chem. Soc. 119, 3413–3414.

(30) Light, K. M., Hangasky, J. A., Knapp, M. J., and Solomon, E. I. (2013) Spectroscopic Studies of the Mononuclear Non-Heme Fe-II Enzyme FIH: Second-Sphere Contributions to Reactivity. *J. Am. Chem. Soc.* 135, 9665–9674.

(31) Neidig, M. L., Brown, C. D., Light, K. M., Fujimori, D. G., Nolan, E. M., Price, J. C., Barr, E. W., Bollinger, J. M., Krebs, C., Walsh, C. T., and Solomon, E. I. (2007) CD and MCD of CytC3 and taurine dioxygenase: Role of the facial triad in *a*-KG-dependent oxygenases. *J. Am. Chem. Soc.* 129, 14224–14231.

(32) Price, J. C., Barr, E. W., Tirupati, B., Bollinger, J. M., and Krebs, C. (2003) The First Direct Characterization of a High-Valent Iron Intermediate in the Reaction of an  $\alpha$ -Ketoglutarate-Dependent Dioxygenase: A High-Spin Fe(IV) Complex in Taurine/ $\alpha$ -Ketoglutarate Dioxygenase (TauD) from *Escherichia coli*. *Biochemistry* 42, 7497–7508.

(33) Riggs-Gelasco, P. J., Price, J. C., Guyer, R. B., Brehm, J. H., Barr, E. W., Bollinger, J. M., and Krebs, C. (2004) EXAFS spectroscopic evidence for an Fe=O unit in the Fe(IV) intermediate observed during oxygen activation by taurine: $\alpha$ -ketoglutarate dioxygenase. *J. Am. Chem. Soc.* 126, 8108–8109.

(34) Proshlyakov, D. A., Henshaw, T. F., Monterosso, G. R., Ryle, M. J., and Hausinger, R. P. (2004) Direct detection of oxygen intermediates in the non-heme Fe enzyme taurine/ $\alpha$ -ketoglutarate dioxygenase. J. Am. Chem. Soc. 126, 1022–1023.

(35) Hoffart, L. M., Barr, E. W., Guyer, R. B., Bollinger, J. M., and Krebs, C. (2006) Direct spectroscopic detection of a C-H-cleaving high-spin Fe(IV) complex in a prolyl-4-hydroxylase. *Proc. Natl. Acad. Sci. U.S.A.* 103, 14738–14743.

(36) Price, J. C., Barr, E. W., Glass, T. E., Krebs, C., and Bollinger, J. M. (2003) Evidence for Hydrogen Abstraction from C1 of Taurine by the High-Spin Fe(IV) Intermediate Detected during Oxygen Activation by Taurine: $\alpha$ -Ketoglutarate Dioxygenase (TauD). J. Am. Chem. Soc. 125, 13008–13009.

(37) Ryle, M. J., Liu, A., Muthukumaran, R. B., Ho, R. Y. N., Koehntop, K. D., McCracken, J., Que, L., and Hausinger, R. P. (2003)  $O_{2^{-}}$  and  $\alpha$ -Ketoglutarate-Dependent Tyrosyl Radical Formation in TauD, an  $\alpha$ -Keto Acid-Dependent Non-Heme Iron Dioxygenase. *Biochemistry* 42, 1854–1862.

(38) Saban, E., Flagg, S., and Knapp, M. (2011) Uncoupled  $O_2$ -activation in the human HIF-asparaginyl hydroxylase, FIH, does not produce reactive oxygen species. *JBIC*, *J. Biol. Inorg. Chem.* 105, 630–636.

(39) Solomon, E. I., Brunold, T. C., Davis, M. I., Kemsley, J. N., Lee, S.-K., Lehnert, N., Neese, F., Skulan, A. J., Yang, Y.-S., and Zhou, J. (2000) Geometric and Electronic Structure/Function Correlations in Non-Heme Iron Enzymes. *Chem. Rev.* 100, 235–350.

(40) Saban, E., Chen, Y.-H., Hangasky, J., Taabazuing, C., Holmes, B., and Knapp, M. (2011) The second coordination sphere of FIH controls hydroxylation. *Biochemistry 50*, 4733–4740.

(41) Borowski, T., Bassan, A., and Siegbahn, P. E. M. (2004) Mechanism of dioxygen activation in 2-oxoglutarate-dependent enzymes: A hybrid DFT study. *Chem.—Eur. J.* 10, 1031–1041.

(42) De Visser, S. P. (2007) Can the peroxosuccinate complex in the catalytic cycle of taurine/ $\alpha$ -ketoglutarate dioxygenase (TauD) act as an alternative oxidant? *Chem. Commun.*, 171–173.

(43) Diebold, A. R., Brown-Marshall, C. D., Neidig, M. L., Brownlee, J. M., Moran, G. R., and Solomon, E. I. (2011) Activation of  $\alpha$ -Keto Acid-Dependent Dioxygenases: Application of an {FeNO}<sub>7</sub>/{FeO}<sub>8</sub> Methodology for Characterizing the Initial Steps of O<sub>2</sub> Activation. *J. Am. Chem. Soc.* 133, 18148–18160.

(44) Ye, S., Riplinger, C., Hansen, A., Krebs, C., Bollinger, J. M., and Neese, F. (2012) Electronic Structure Analysis of the Oxygen-Activation Mechanism by FeII- and  $\alpha$ -Ketoglutarate ( $\alpha$ KG)-Dependent Dioxygenases. *Chem.*—*Eur. J.* 18, 6555–6567.

(45) Mirica, L. M., McCusker, K. P., Munos, J. W., Liu, H., and Klinman, J. P. (2008) <sup>18</sup>O kinetic isotope effects in non-heme iron enzymes: Probing the nature of Fe/O<sub>2</sub> intermediates. *J. Am. Chem. Soc.* 130, 8122–8123.

(46) Ryle, M. J., Padmakumar, R., and Hausinger, R. P. (1999) Stopped-Flow Kinetic Analysis of *Escherichia coli* Taurine/ $\alpha$ -Ketoglutarate Dioxygenase: Interactions with  $\alpha$ -Ketoglutarate, Taurine, and Oxygen. *Biochemistry* 38, 15278–15286.

(47) Flashman, E., Hoffart, L. M., Hamed, R. B., Bollinger, J. M., Krebs, C., and Schofield, C. J. (2010) Evidence for the slow reaction of hypoxia-inducible factor prolyl hydroxylase 2 with oxygen. *FEBS J.* 277, 4089–4099.

(48) Dann, C. E., Bruick, R. K., and Deisenhofer, J. (2002) Structure of factor-inhibiting hypoxia-inducible factor 1: An asparaginyl hydroxylase involved in the hypoxic response pathway. *Proc. Natl. Acad. Sci. U.S.A.* 99, 15351–15356.

(49) Lee, C., Kim, S. J., Jeong, D. G., Lee, S. M., and Ryu, S. E. (2003) Structure of Human FIH-1 Reveals a Unique Active Site Pocket and Interaction Sites for HIF-1 and von Hippel-Lindau. *J. Biol. Chem.* 278, 7558–7563.

(50) Chen, Y. H., Comeaux, L. M., Herbst, R. W., Saban, E., Kennedy, D. C., Maroney, M. J., and Knapp, M. J. (2008) Coordination changes and auto-hydroxylation of FIH-1: Uncoupled  $O_2$ -activation in a human hypoxia sensor. *J. Inorg. Biochem.* 102, 2120–2129.

(51) Frantom, P. A., and Fitzpatrick, P. F. (2003) Uncoupled forms of tyrosine hydroxylase unmask kinetic isotope effects on chemical steps. J. Am. Chem. Soc. 125, 16190–16191.

(52) Loeb, K. E., Westre, T. E., Kappock, T. J., Mitic, N., Glasfeld, E., Caradonna, J. P., Hedman, B., Hodgson, K. O., and Solomon, E. I. (1997) Spectroscopic characterization of the catalytically competent ferrous site of the resting, activated, and substrate-bound forms of phenylalanine hydroxylase. *J. Am. Chem. Soc.* 119, 1901–1915.

(53) Hegg Whiting, A. K., Saari, R. E., McCracken, J., Hausinger, R. P., and Que, L., Jr. (1999) Herbicide degrading  $\alpha$ -keto acid dependent enzyme Tfda: Metal coordination environment and mechanistic insights. *Biochemistry* 38, 16714–16726.

(54) Bollinger, J. M., Price, J. C., Hoffart, L. M., Barr, E. W., and Krebs, C. (2005) Mechanism of Taurine: $\alpha$ -Ketoglutarate Dioxygenase (TauD) from *Escherichia coli. Eur. J. Inorg. Chem.* 2005, 4245–4254.

(55) Coleman, M. L., McDonough, M. A., Hewitson, K. S., Coles, C., Mecinović, J., Edelmann, M., Cook, K. M., Cockman, M. E., Lancaster, D. E., Kessler, B. M., Oldham, N. J., Ratcliffe, P. J., and Schofield, C. J. (2007) Asparaginyl Hydroxylation of the Notch Ankyrin Repeat Domain by Factor Inhibiting Hypoxia-inducible Factor. *J. Biol. Chem.* 282, 24027–24038.

(56) Koivunen, P., Hirsilä, M., Günzler, V., Kivirikko, K. I., and Myllyharju, J. (2004) Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4-hydroxylases. J. Biol. Chem. 279, 9899–9904.

(57) Linke, S., Stojkoski, C., Kewley, R. J., Booker, G. W., Whitelaw, M. L., and Peet, D. J. (2004) Substrate requirements of the oxygensensing asparaginyl hydroxylase factor-inhibiting hypoxia-inducible factor. *J. Biol. Chem.* 279, 14391–14397.

(58) Yang, M., Chowdhury, R., Ge, W., Hamed, R. B., McDonough, M. A., Claridge, T. D. W., Kessler, B. M., Cockman, M. E., Ratcliffe, P. J., and Schofield, C. J. (2011) Factor-inhibiting hypoxia-inducible factor (FIH) catalyses the post-translational hydroxylation of histidinyl residues within ankyrin repeat domains. *FEBS J.* 278, 1086–1097.

(59) Yang, M., Hardy, A. P., Chowdhury, R., Loik, N. D., Scotti, J. S., McCullagh, J. S. O., Claridge, T. D. W., McDonough, M. A., Ge, W., and Schofield, C. J. (2013) Substrate Selectivity Analyses of Factor Inhibiting Hypoxia-Inducible Factor. *Angew. Chem., Int. Ed. 52*, 1700– 1704.

(60) Wilkins, S. E., Karttunen, S., Hampton-Smith, R. J., Murchland, I., Chapman-Smith, A., and Peet, D. J. (2012) Factor Inhibiting HIF (FIH) Recognizes Distinct Molecular Features within Hypoxiainducible Factor- $\alpha$  (HIF- $\alpha$ ) versus Ankyrin Repeat Substrates. *J. Biol. Chem.* 287, 8769–8781.